Nabriva Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Nabriva Therapeutics has a total shareholder equity of $3.3M and total debt of $5.2M, which brings its debt-to-equity ratio to 158.5%. Its total assets and total liabilities are $31.8M and $28.5M respectively.
Key information
158.5%
Debt to equity ratio
US$5.22m
Debt
Interest coverage ratio | n/a |
Cash | US$12.41m |
Equity | US$3.29m |
Total liabilities | US$28.47m |
Total assets | US$31.77m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NTY's short term assets ($31.1M) exceed its short term liabilities ($27.6M).
Long Term Liabilities: NTY's short term assets ($31.1M) exceed its long term liabilities ($867.0K).
Debt to Equity History and Analysis
Debt Level: NTY has more cash than its total debt.
Reducing Debt: NTY's debt to equity ratio has increased from 0.3% to 158.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NTY has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: NTY has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.8% each year.